Dendreon News

All day and every day, some of the stock market's best and brightest traders and money managers share their ideas, insights and analysis in real-time on Minyanville's Buzz & Banter .

Bristol-Myers Squibb Company : Jim Cramer ranked this stock a Buy . The stock closed at $32.08, its 52-week high is $35.44, and its 52-week low is $24.97. Buffalo Wild Wings Inc.

Dr Pepper Snapple Group, Inc. today announced that its Board of Directors declared a quarterly dividend of $0.34 per share on the company's common stock - a 6.3% increase in the dividend rate.

The First Trust NYSE Arca Biotechnology Index Fund ETF is seeing unusually high volume in afternoon trading Wednesday, with over 144,000 shares traded versus three month average volume of about 129,000. Shares of FBT were down about 1.2% on the day.

Sprint Nextel Corp. : FBR's channel checks indicate Sprint's solid execution continues and the firm reiterates an Outperform rating on the stock ahead of the company's Q4 results on February 8. FBR believes Sprint is on track to exceed consensus expectations in FY12.

Shares of Dendreon spiked today on news that sales of Provenge, its so-called vaccine against prostate cancer, rose sharply last quarter .

Dendreon Corporation : Dendreon February 17 and 20 calls are active on total call volume of 55K contracts .

Prior to joining the firm, Down had his own company providing services as a consultant pharmaceutical physician for big pharmas such as Pfizer and GSK.

WASHINGTON &#8212 Shares of biotech drugmaker Dendreon Corp. rose Monday after federal health regulators published a critical review of rival Amgen's drug for prostate cancer.

Dendreon was upgraded by Bank of America from an "underperform" rating to a "neutral" rating in a research note issued on Friday.

Dendreon Corporation recently announced the appointment of a new chief executive officer .

Dendreon Corporation recently announced the appointment of a new chief executive officer .

The decision of John Johnson to go to Dendreon as CEO and Chairman after only one year at the helm as CEO of Savient can only be looked at as a negative.

IMUC: A recent financing deal brought shares of Immunocellular Therapeutics crashing down towards a dollar earlier this year, but encouraging pipeline news, high volume and new institutional interest has quickly revived the share price and the stock closed Wednesday seventy percent higher than is January lows.

Dendreon Corporation A names board member John Johnson as its president and Chief Executive Officer, beginning June 30.

I think that most physicians and investors were aware that the analysis of Dendreon's Provenge in the Phase III IMPACT Trials understated its effect on survival because of the use of frozen Provenge in the control group.

February 1, 2012 - Dendreon Corporation today announced that management will host a conference call on Monday, February 27, 2012, at 4:30 p.m. ET to review fourth quarter and year-end financial results.

NEW YORK - Stocks that moved substantially or traded heavily Wednesday on the New York Stock Exchange and Nasdaq Stock Market: NYSE AOL Inc., up $1.55 at $17.76 The internet company said its fourth-quarter net income fell sharply, but the company's advertising revenue rose 10 percent.

Dendreon 's stock had its "neutral" rating reiterated by equities research analysts at Robert W. Baird in a research note issued to investors on Wednesday.

Dendreon Corp. : Cantor believes John Johnson's background in marketing and cost structure could lead to a restructuring within Dendreon in 2012.